Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Renal Insufficiency

ClinicalTrials.gov lists 7,294 trials for Renal Insufficiency or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 76.

MeSH D051437 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 668 Phase 1/2 Phase 1/2 129 Phase 2 Phase 2 625 Phase 2/3 Phase 2/3 105 Phase 3 Phase 3 593 Phase 4 Phase 4 723 Not applicable Not applicable 2,273 Observational Observational 2,170 Phase 1 Phase 1 668 Phase 1/2 Phase 1/2 129 Phase 2 Phase 2 625 Phase 2/3 Phase 2/3 105 Phase 3 Phase 3 593 Phase 4 Phase 4 723 Not applicable Not applicable 2,273 Observational Observational 2,170

Trials per phase (log scale)

1 more section with rows

1,368 of the 7,294 trials are tagged with Renal Insufficiency itself; the rest are tagged with a narrower condition beneath it.

Get the Renal Insufficiency report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Renal Insufficiency trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 17 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 464

1990: 1 trials (Observational 1) 1991: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 2 trials (Observational 1, Phase 2 1) 1994: 2 trials (Observational 2) 1995: 4 trials (Not applicable 2, Phase 3 1, Phase 2 1) 1996: 5 trials (Observational 2, Not applicable 2, Phase 3 1) 1997: 9 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 5) 1998: 9 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 1) 1999: 13 trials (Observational 1, Not applicable 3, Phase 3 5, Phase 2 1, Phase 1 3) 2000: 18 trials (Observational 10, Not applicable 2, Phase 3 4, Phase 2 2) 2001: 29 trials (Observational 9, Not applicable 2, Phase 4 7, Phase 3 5, Phase 2 2, Phase 1 4) 2002: 47 trials (Observational 3, Not applicable 7, Phase 4 18, Phase 3 9, Phase 2/3 2, Phase 2 8) 2003: 68 trials (Observational 12, Not applicable 8, Phase 4 16, Phase 3 12, Phase 2/3 1, Phase 2 8, Phase 1/2 4, Phase 1 7) 2004: 104 trials (Observational 22, Not applicable 19, Phase 4 27, Phase 3 17, Phase 2/3 2, Phase 2 10, Phase 1/2 3, Phase 1 4) 2005: 140 trials (Observational 20, Not applicable 29, Phase 4 34, Phase 3 21, Phase 2/3 4, Phase 2 22, Phase 1/2 6, Phase 1 4) 2006: 166 trials (Observational 40, Not applicable 22, Phase 4 29, Phase 3 23, Phase 2/3 5, Phase 2 29, Phase 1/2 4, Phase 1 14) 2007: 163 trials (Observational 43, Not applicable 28, Phase 4 24, Phase 3 26, Phase 2/3 10, Phase 2 15, Phase 1/2 2, Phase 1 15) 2008: 247 trials (Observational 64, Not applicable 54, Phase 4 43, Phase 3 28, Phase 2/3 6, Phase 2 27, Phase 1/2 3, Phase 1 22) 2009: 233 trials (Observational 54, Not applicable 43, Phase 4 44, Phase 3 32, Phase 2/3 7, Phase 2 30, Phase 1/2 5, Phase 1 18) 2010: 261 trials (Observational 76, Not applicable 46, Phase 4 35, Phase 3 31, Phase 2/3 8, Phase 2 37, Phase 1/2 3, Phase 1 25) 2011: 273 trials (Observational 81, Not applicable 61, Phase 4 31, Phase 3 25, Phase 2/3 8, Phase 2 25, Phase 1/2 7, Phase 1 35) 2012: 252 trials (Other 1, Observational 63, Not applicable 70, Phase 4 29, Phase 3 33, Phase 2/3 1, Phase 2 27, Phase 1/2 5, Phase 1 23) 2013: 311 trials (Other 1, Observational 73, Not applicable 92, Phase 4 45, Phase 3 27, Phase 2/3 2, Phase 2 27, Phase 1/2 5, Phase 1 39) 2014: 301 trials (Observational 85, Not applicable 96, Phase 4 17, Phase 3 18, Phase 2/3 3, Phase 2 34, Phase 1/2 14, Phase 1 34) 2015: 342 trials (Observational 90, Not applicable 113, Phase 4 41, Phase 3 29, Phase 2/3 3, Phase 2 19, Phase 1/2 10, Phase 1 37) 2016: 324 trials (Observational 93, Not applicable 118, Phase 4 27, Phase 3 24, Phase 2/3 6, Phase 2 28, Phase 1/2 1, Phase 1 27) 2017: 328 trials (Observational 94, Not applicable 127, Phase 4 22, Phase 3 23, Phase 2/3 2, Phase 2 24, Phase 1/2 5, Phase 1 31) 2018: 331 trials (Observational 109, Not applicable 125, Phase 4 28, Phase 3 24, Phase 2/3 1, Phase 2 20, Phase 1/2 2, Phase 1 22) 2019: 381 trials (Observational 120, Not applicable 133, Phase 4 30, Phase 3 28, Phase 2/3 5, Phase 2 24, Phase 1/2 2, Phase 1 39) 2020: 320 trials (Observational 120, Not applicable 112, Phase 4 23, Phase 3 15, Phase 2 22, Phase 1/2 3, Phase 1 25) 2021: 403 trials (Observational 140, Not applicable 135, Phase 4 22, Phase 3 16, Phase 2/3 6, Phase 2 34, Phase 1/2 5, Phase 1 45) 2022: 401 trials (Observational 142, Not applicable 132, Phase 4 22, Phase 3 26, Phase 2/3 4, Phase 2 28, Phase 1/2 5, Phase 1 42) 2023: 418 trials (Observational 133, Not applicable 156, Phase 4 23, Phase 3 25, Phase 2/3 6, Phase 2 27, Phase 1/2 8, Phase 1 40) 2024: 464 trials (Observational 167, Not applicable 163, Phase 4 33, Phase 3 19, Phase 2/3 7, Phase 2 28, Phase 1/2 6, Phase 1 41) 2025: 428 trials (Observational 133, Not applicable 176, Phase 4 19, Phase 3 20, Phase 2/3 4, Phase 2 31, Phase 1/2 13, Phase 1 32)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 425
2025 428
2024 464
2023 418
2022 401
2021 403
2020 320
2019 381
2018 331
2017 328

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 480 trials starting in 2026 and about 460 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 495 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 4,582 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Renal Insufficiency trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 668
Phase 1/2 129
Phase 2 625
Phase 2/3 105
Phase 3 593
Phase 4 723
Not applicable 2,273
Observational 2,170
Expanded access 8

How many Renal Insufficiency trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 376
Recruiting 702
Enrolling by invitation 59
Active, not recruiting 238
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Renal Insufficiency trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 76
Amgen 73
Bayer 65
Novartis Pharmaceuticals 51
Vantive Health LLC 45

Which drugs are being tested for Renal Insufficiency? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
EPOETIN ALFA 61
BMS-512148 53
Finerenone 40
.spironolactone 33
Cinacalcet 33

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IR Tacrolimus 56
darbepoetin alfa SF 54
Paricalitol 47
sodium bicarbonate 8.4% 40
Empagliflozine 39

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Renal Insufficiency trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,150 250
Hospitalizations 2,405 4
Other 2,059 6
Cardiac failure congestive 2,021 141
Sepsis 1,946 181

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Renal Insufficiency? (922)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nature medicine 2026 Yes
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment. Expert opinion on investigational drugs 2025 Yes
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone. British journal of clinical pharmacology 2025 Yes
Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open-Label, Parallel-Group, Single-Center Studies. Clinical and translational science 2025 Yes
The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration. British journal of clinical pharmacology 2025 Yes

Showing 5 of 922 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages